| Literature DB >> 35562045 |
Feifan Chen1, Yan Tian1, Lixin Zhang1, Yuan Shi2.
Abstract
OBJECTIVES: To explore household transmissibility of SARS-CoV-2 in children in new-variants dominating periods.Entities:
Keywords: COVID-19; Child; Household transmission; SARS-CoV-2
Mesh:
Year: 2022 PMID: 35562045 PMCID: PMC9091150 DOI: 10.1016/j.ijid.2022.05.016
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 12.074
Studies included in meta-analysis of household SAR.
| Author (year) | Country | Study type | Cluster size | Public lockdown | Diagnostic method | Follow-up (days) | Quality | |
|---|---|---|---|---|---|---|---|---|
| Brazil | Cross-sectional and analytical study | NA | Yes | RT-PCR | 14 | Medium | ||
| United States | Retrospective study | 183 | NA | RT-PCR | NA | High | ||
| Canada | Prospective study | 180 | NA | RT-PCR | 14 | High | ||
| Switzerland | Cross-sectional population serosurvey | 2267 | Yes | Serological test | NA | High | ||
| China | Retrospective cohort study | NA | Yes | RT-PCR | 14 | High | ||
| Italy | Case-control study | NA | NA | RT-PCR | NA | Medium | ||
| United States | Prospective study | 100 | NA | RT-PCR | 28 | High | ||
| Malaysia | Retrospective study | 28 | NA | RT-PCR | 14 | Medium | ||
| The Netherlands | Retrospective study | NA | NA | RT-PCR | 10 | Medium | ||
| United States | Prospective study | 127 | NA | RT-PCR | 14 | High | ||
| Switzerland | Cross-sectional epidemiological study | NA | Yes | Serological test | 14 | Medium | ||
| Germany | Seroprevalence study | 106 | NA | Serological test | NA | Medium | ||
| England | Retrospective study | NA | NA | RT-PCR | 14 | High | ||
| China | Retrospective cohort study | NA | Yes | RT-PCR | 14 | High | ||
| China | Retrospective cohort, multicenter study | 314 | Yes | RT-PCR | NA | Medium | ||
| Norway | Cohort study | NA | NA | RT-PCR | 10 | High | ||
| China | Retrospective cohort study | 195 | Yes | RT-PCR | 14 | High | ||
| South Korea | Retrospective observational study | NA | NA | RT-PCR | NA | Medium | ||
| Greece | Retrospective cohort study | 40 | Yes | RT-PCR | NA | Medium | ||
| Japan | Cohort study | NA | Yes | RT-PCR | 14 | Medium | ||
| United States | 58 | Yes | RT-PCR | 14 | High | |||
| China | Retrospective cohort study | 24985 | Yes | RT-PCR | ≥22 | High | ||
| China | Retrospective study | 105 | NA | RT-PCR | 14 | Medium | ||
| United States | Prospective study | 15 | NA | RT-PCR | 14 | High | ||
| England | Prospective case-ascertained study | 329 | NA | RT-PCR | 14 | High | ||
| Denmark | Retrospective study | 24693 | NA | RT-PCR | 14 | High | ||
| United States | Prospective case-ascertained study | 302 | NA | RT-PCR | 14 | High | ||
| United States | Retrospective cohort study | NA | NA | RT-PCR | NA | Medium | ||
| England | Prospective cohort study | NA | NA | RT-PCR | NA | Medium | ||
| Japan | Cohort study | 87 | Yes | RT-PCR | 14 | Medium | ||
| Bosnia and Herzegovina | Prospective observational study | 360 | NA | RT-PCR | 28 | High | ||
| Malaysia | Retrospective observational study | 185 | Yes | RT-PCR | 14 | Medium | ||
| Singapore | Retrospective cohort study | NA | Yes | RT-PCR | 14 | High | ||
| Japan | Cross-sectional study | 183 | Yes | RT-PCR | NA | Medium | ||
| Japan | Observational study | 580 | NA | RT-PCR | NA | High | ||
| South Korea | Cohort study | NA | NA | RT-PCR | 14 | Medium | ||
| The Netherlands | Prospective cohort study | 55 | NA | RT-PCR | NA | High | ||
| United States | Retrospective study | 155 | Yes | RT-PCR | NA | High | ||
| South Korea | Prospective study | 25 | NA | NA | NA | High | ||
| Spain | Prospective, observational study | 1108 | Yes | RT-PCR | NA | Medium | ||
| Germany | Multicenter, cross-sectional study | 405 | NA | Serological test | NA | High | ||
| Japan | Cross-sectional study | NA | NA | RT-PCR | 14 | Medium | ||
| United States | Prospective study | 127 | NA | RT-PCR | 14 | High | ||
| China | Retrospective cohort study | 124 | NA | RT-PCR | 14 | High | ||
| China | Retrospective case series | 85 | Yes | RT-PCR | 14 | High | ||
| China | Prospective observational study | 35 | NA | RT-PCR | NA | Medium | ||
| United States | Prospective cohort study | NA | NA | RT-PCR | 14 | High | ||
| Singapore | Prospective study | 137 | NA | RT-PCR | 14 | Medium | ||
NA, not applicable; RT-PCR, reverse transcription polymerase chain reaction; SAR, secondary attack rate.
Case analyses of household pediatric COVID-19 infections.
| Characteristics | Cluster (n = 78), % | Secondary cases (n = 207), % |
|---|---|---|
| Child as the index case | 8 (10.3) | 16 (7.7) |
| Adult as the index case | 70 (89.7) | 191 (92.3) |
| Child as the contacts | 47 (60.3) | 62 (30.0) |
| Adult as the contacts | 77 (98.7) | 145 (70.0) |
COVID-19, coronavirus disease.
Figure 1Pooled household SAR of child contacts. CI, confidence interval; SAR, secondary attack rate.
Subgroup analyses on household SAR of child contacts.
| Subgroups | No. of studies | SAR (95% CI) | I2 | |
|---|---|---|---|---|
| <0.01 | ||||
| 2019-Feb, 2021 | 31 | 0.18 (0.13–0.25) | 99% | |
| Feb-Nov, 2021 | 9 | 0.39 (0.30–0.48) | 97% | |
| Nov, 2021-2022 | 2 | 0.51 (0.47–0.54) | 0% | |
| <0.01 | ||||
| Wild type | 33 | 0.20 (0.14–0.26) | 99% | |
| Alpha | 3 | 0.42 (0.23–0.62) | 94% | |
| Delta | 5 | 0.35 (0.25–0.45) | 98% | |
| Omicron | 2 | 0.56 (0.51–0.61) | 20% |
CI, confidence interval; SAR, secondary attack rate; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2Subgroup analyses on household SAR of child contacts in different age groups. CI, confidence interval; RR, risk ratio; SAR, secondary attack rate.
Figure 3Household SAR comparison between child and adult contacts. CI, confidence interval; RR, risk ratio; SAR, secondary attack rate.
Subgroup analyses of household SAR comparison between child and adult contacts.
| Subgroups | No. of studies | RR (95% CI) | I2 | |
|---|---|---|---|---|
| <0.01 | ||||
| 2019–June, 2020 | 27 | 0.62 (0.52–0.75) | 95% | <0.01 |
| February–November, 2021 | 9 | 0.98 (0.86–1.12) | 80% | >0.05 |
| November, 2021–2022 | 2 | 1.09 (0.89–1.34) | 73% | >0.05 |
| <0.01 | ||||
| Wild type | 29 | 0.65 (0.55–0.77) | 95% | <0.01 |
| Alpha | 3 | 1.04 (0.76–1.42) | 76% | >0.05 |
| Delta | 5 | 0.99 (0.82–1.19) | 88% | >0.05 |
| Omicron | 2 | 1.09 (0.88–1.35) | 74% | >0.05 |
CI, confidence interval; RR, relative risk; SAR, secondary attack rate; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 4Comparison on household SAR between child and adult index cases. CI, confidence interval; RR, risk ratio; SAR, secondary attack rate.